IQVIA Biotech launches in Asia Pacific, Japan
New Delhi: With the goal of substantial clinical development, IQVIA recently announced the Japan and Asia Pacific (JAPAC) expansion of IQVIA Biotech, a tailored approach to delivering integrated clinical and commercial solutions for biotech and emerging biopharma companies.
IQVIA Biotech in Japan and Asia-Pacfic (JAPAC) provides comprehensive, flexible and fit-for purpose clinical and commercial solutions specifically tailored to meet the regional and global aspirations of dynamic and fast-moving emerging biotech and biopharma companies.
IQVIA Biotech teams use lean operating procedures and scientific specialization to deliver flexible solutions, powered by IQVIA's technology enabled services, that can help innovative companies reach their drug development and commercialization milestones.
"Biotech companies are fueling rapid development of biologics, drugs, and vaccines, and when they succeed, we all succeed," said Richard Staub, president, Research & Development Solutions at IQVIA. "By launching IQVIA Biotech in JAPAC, we can support the aspirations of biotech customers with agile solutions and resources dedicated to supporting smallercompanies."
Launched in North America and Europe in early 2019, IQVIA Biotech was designed in response to the needs of biotech customers for transparent and fit-for-purpose clinical processes with dedicated, therapeuticallyaligned partners. Since its launch, IQVIA Biotech has initiatedhundreds ofnew trials for biotech companies, including COVID-19 trials.
With specialized expertise in oncology, central nervous system disorders, dermatology, and cardiovascular and rare diseases, IQVIA Biotech has regional headquarters in Singapore and offices in 15 countries across the region. The dedicated IQVIA Biotech teams in JAPAC are equipped to meet the unique needs of biotech customers by creating intelligent connections across the drug development process.
"Biotech companies have increasing global aspirations, and demand is also growing from global emerging customers for delivery in this region," said Dr Senthil Sockalingam, head, IQVIA Biotech, JAPAC and chief medical officer, APAC. "IQVIA Biotech allows us to offer customersa truly seamless experience fully aligned with flexible and tailored integrated solutions delivered by specialized teams."
As per the firm, IQVIA Biotech in JAPAC partners with emerging biotechs and biopharma innovators to help them achieve their global ambitions, and support with JAPAC clinical development needs, with the aim of delivering compelling results to all stakeholders and ultimately improving health outcomes for patients.
The IQVIA Biotech solutions suite in JAPAC is a custom-built delivery model that mirrors biotech organizations to offer simplified operating procedures, reduced complexity and specialized teams to provide a more agile way for emerging biotech and biopharma companies to reach their clinical and commercial milestones.
"As IQVIA Biotech in JAPAC, we focus on providing tailored clinical development expertise and solutions. Additionally, we seamlessly support across other areas of the development lifecycle, specifically providing asset valuation and due diligence, drug development strategy and analytics, launch strategy and planning, as well as commercialization and lifecycle management. " IQVIA Biotech added in its release.
Also Read:10% of anaphylaxis Patients require Multiple Dose of Epinephrine, says study
